Page 17 - 《中国药房》2023年11期

glimepiride in East-Asian patients with type 2 diabetes in term cardiovascular end point trial of lixisenatide versus
a multicentre，double-blind，randomized，parallel-arm，ac‐ placebo[J]. Am Heart J，2015，169（5）：631-638.
tive comparator，phase Ⅲ trial[J]. Diabetes Obes Metab， [34] PFEFFER M A，CLAGGETT B，DIAZ R，et al. Lixisena‐
2018，20（9）：2121-2130. tide in patients with type 2 diabetes and acute coronary
[24] WANG W Q，NEVÁREZ L，FILIPPOVA E，et al. Effi‐ syndrome[J]. N Engl J Med，2015，373（23）：2247-2257.
cacy and safety of once-weekly dulaglutide versus insulin [35] KRISTENSEN S L，RØRTH R，JHUND P S，et al. Cardio‐
glargine in mainly Asian patients with type 2 diabetes mel‐ vascular，mortality，and kidney outcomes with GLP-1 re‐
litus on metformin and/or a sulphonylurea：a 52-week ceptor agonists in patients with type 2 diabetes：a syste-
open-label，randomized phase Ⅲ trial[J]. Diabetes Obes matic review and meta-analysis of cardiovascular outcome
Metab，2019，21（2）：234-243. trials[J]. Lancet Diabetes Endocrinol，2019，7（10）：
[25] JI L N，DONG X L，LI Y M，et al. Efficacy and safety of 776-785.
once-weekly semaglutide versus once-daily sitagliptin as [36] MANN J F E，ØRSTED D D，BROWN-FRANDSEN K，
add-on to metformin in patients with type 2 diabetes in et al. Liraglutide and renal outcomes in type 2 diabetes[J].
SUSTAIN China：a 30-week，double-blind，phase 3a，ran‐ N Engl J Med，2017，377（9）：839-848.
domized trial[J]. Diabetes Obes Metab，2021，23（2）： [37] GERSTEIN H C，COLHOUN H M，DAGENAIS G R，et
404-414. al. Dulaglutide and renal outcomes in type 2 diabetes：an
[26] SHUAI Y，YANG G Y，ZHANG Q，et al. Efficacy and exploratory analysis of the REWIND randomised，
safety of polyethylene glycol loxenatide monotherapy in placebo-controlled trial[J]. Lancet，2019，394（10193）：
type 2 diabetes patients：a multicentre，randomized， 131-138.
double-blind，placebo-controlled phase 3a clinical trial[J]. [38] MARSO S P，BAIN S C，CONSOLI A，et al. Semaglutide
Diabetes Obes Metab，2021，23（1）：116-124. and cardiovascular outcomes in patients with type 2 diabe‐
[27] GAO F，LYU X F，MO Z H，et al. Efficacy and safety of tes[J]. N Engl J Med，2016，375（19）：1834-1844.
polyethylene glycol loxenatide as add-on to metformin in [39] BETHEL M A，MENTZ R，MERRILL P，et al. Renal out‐
patients with type 2 diabetes：a multicentre，randomized， comes in the Exenatide Study of Cardiovascular Event
double-blind，placebo-controlled，phase 3b trial[J]. Diabe‐ Lowering （EXSCEL）[J]. Diabetes，2018，67（Suppl
tes Obes Metab，2020，22（12）：2375-2383. 1）：552.
[28] MARSO S P，DANIELS G H，BROWN-FRANDSEN K， [40] MUSKIET M H A，TONNEIJCK L，HUANG Y，et al.
et al. Liraglutide and cardiovascular outcomes in type 2 Lixisenatide and renal outcomes in patients with type 2
diabetes[J]. N Engl J Med，2016，375（4）：311-322. diabetes and acute coronary syndrome：an exploratory
[29] GERSTEIN H C，COLHOUN H M，DAGENAIS G R，et analysis of the ELIXA randomised，placebo-controlled
al. Dulaglutide and cardiovascular outcomes in type 2 dia‐ trial[J]. Lancet Diabetes Endocrinol，2018，6（11）：
betes （REWIND）：a double-blind，randomised placebo- 859-869.
controlled trial[J]. Lancet，2019，394（10193）：121-130. [41] ELSAYED N A，ALEPPO G，ARODA V R，et al. 8. obe‐
[30] COSMI F，LAINI R，NICOLUCCI A. Semaglutide and sity and weight management for the prevention and treat‐
cardiovascular outcomes in patients with type 2 diabetes ment of type 2 diabetes：standards of care in diabetes：2023
[J]. N Engl J Med，2017，376（9）：890. [J]. Diabetes Care，2023，46（Suppl 1）：S128-S139.
[31] MENTZ R J，BETHEL M A，GUSTAVSON S，et al. Base‐ [42] KENDALL D M，CUDDIHY R M，BERGENSTAL R M.
line characteristics of patients enrolled in the Exenatide Clinical application of incretin-based therapy：therapeutic
Study of Cardiovascular Event Lowering （EXSCEL）[J]. potential，patient selection and clinical use[J]. Eur J Intern
Am Heart J，2017，187：1-9. Med，2009，20（Suppl 2）：S329-S339.
[32] HOLMAN R R，BETHEL M A，MENTZ R J，et al. Ef‐ [43] PENG H，WANT L L，ARODA V R. Safety and tolerabi-
fects of once-weekly exenatide on cardiovascular out‐ lity of glucagon-like peptide-1 receptor agonists utilizing
comes in type 2 diabetes[J]. N Engl J Med，2017，377 data from the exenatide clinical trial development program
（13）：1228-1239. [J]. Curr Diab Rep，2016，16（5）：44.
[33] BENTLEY-LEWIS R，AGUILAR D，RIDDLE M C，et al. [44] FINEMAN M S，MACE K F，DIAMANT M，et al. Clini‐
Rationale，design，and baseline characteristics in evalua‐ cal relevance of anti-exenatide antibodies：safety，efficacy
tion of lixisenatide in acute coronary syndrome，a long- and cross-reactivity with long-term treatment[J]. Diabetes

中国药房 2023年第34卷第11期 China Pharmacy 2023 Vol. 34 No. 11 · 1291 ·